IL304537A - Gastric residence systems for administration of risperidone - Google Patents

Gastric residence systems for administration of risperidone

Info

Publication number
IL304537A
IL304537A IL304537A IL30453723A IL304537A IL 304537 A IL304537 A IL 304537A IL 304537 A IL304537 A IL 304537A IL 30453723 A IL30453723 A IL 30453723A IL 304537 A IL304537 A IL 304537A
Authority
IL
Israel
Prior art keywords
risperidone
administration
gastric residence
residence systems
systems
Prior art date
Application number
IL304537A
Other languages
Hebrew (he)
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/013027 external-priority patent/WO2022159529A1/en
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of IL304537A publication Critical patent/IL304537A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
IL304537A 2021-01-19 2023-07-17 Gastric residence systems for administration of risperidone IL304537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163139299P 2021-01-19 2021-01-19
PCT/US2022/013027 WO2022159529A1 (en) 2021-01-19 2022-01-19 Gastric residence systems for administration of risperidone

Publications (1)

Publication Number Publication Date
IL304537A true IL304537A (en) 2023-09-01

Family

ID=87849812

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304537A IL304537A (en) 2021-01-19 2023-07-17 Gastric residence systems for administration of risperidone

Country Status (1)

Country Link
IL (1) IL304537A (en)

Similar Documents

Publication Publication Date Title
IL292849A (en) Gastric residence systems for administration of active agents
IL291674A (en) Interconnection of drug administration systems
EP4281049A4 (en) Gastric indwelling systems for the administration of risperidone
IL286518A (en) Capsules and capsule coatings for gastric residence dosage forms
IL275639A (en) Formulation for administration of rna
WO2014204894A3 (en) Vial transfer and injection apparatus and method
IL280883A (en) Systems for the intestinal transfer of medicinal substances
IL288550A (en) Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
IL269256A (en) System for predicting post-surgery prognosis or anticancer drug compatibility of advanced gastric cancer patients
IL286510A (en) Coatings for gastric residence dosage forms
AU2018297348A1 (en) Compositions for parenteral administration of therapeutic agents
IL268127A (en) Treatment comprising oral or gastric administration of edaravone
EP3941445A4 (en) Capsules and capsule coatings for gastric residence dosage forms
IL291603A (en) Remote aggregation of data for drug administration devices
IL316048A (en) Therapeutic applications of crispr type v systems
IL309664A (en) Administration of anti-hpa-1a antibodies
HK40104184A (en) Gastric residence systems for administration of risperidone
ZA202202931B (en) System and method for infusion of drugs
IL290421A (en) Drug delivery system for the delivery of antiviral agents
HK40080659A (en) Gastric residence systems for administration of active agents
GB202307942D0 (en) Computer system for managing dosage timing of tacrolimus
HK40004386A (en) Gastric residence systems for sustained delivery of adamantane-class drugs
HK40075570A (en) Interconnection of drug administration systems
CA3294216A1 (en) Manufacturing methods for gastric residence systems
HK40066496A (en) Capsules and capsule coatings for gastric residence dosage forms